ROCKVILLE, MD – In a recent development, Sensei Biotherapeutics, Inc., a pharmaceutical company based in Rockville, Maryland, concluded its annual stockholders meeting on June 11, 2024, with key decisions made regarding its board composition and auditor appointment. The company, listed on the Nasdaq with the ticker NASDAQ:SNSE, announced the election of three directors and the ratification of its independent registered public accounting firm.
During the annual meeting, which saw a 68.21% turnout of shareholders, the company's stockholders voted on two major proposals. The first proposal involved the election of three individuals to serve on the company's Board of Directors until the 2027 annual meeting of stockholders. Jessie English, James Peyer, and Thomas Ricks were the nominees, and all were successfully elected with the majority of votes cast in their favor.
Jessie English received 9,245,391 votes for and 1,741,495 votes withheld. James Peyer had 9,060,240 votes for and 1,924,942 votes withheld. Thomas Ricks garnered the most support with 10,231,306 votes for and only 756,108 votes withheld. Broker non-votes were reported for each candidate, ranging from 6,120,844 to 6,123,076.
The second proposal was the ratification of Deloitte & Touche LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The appointment was ratified with a significant majority, receiving 16,293,567 votes for, 797,235 votes against, and 17,456 abstentions.
The results of the annual meeting, which are based on a press release statement, reflect the shareholders' confidence in the elected directors and their choice of auditor. Sensei Biotherapeutics, operating under the SIC code for pharmaceutical preparations (2834), is incorporated in Delaware and concluded its meeting with all matters being submitted to a vote, duly recorded.
The company's address, as stated in the SEC filing, is 1405 Research Blvd, Suite 125, Rockville, MD, 20850, with a business phone number of (240) 243-8000. The SEC filing was signed by Christopher W. Gerry, General Counsel and Secretary of Sensei Biotherapeutics, Inc., on June 13, 2024.
In other recent news, Sensei Biotherapeutics has been the focus of attention following several developments. Citi has resumed coverage of Sensei Biotherapeutics, setting the stock to buy with a $4 target, following the company's presentation at the American Society of Clinical Oncology. The firm highlighted the potential of Sensei's drug, SNS-101, in treating various tumor types.
Moreover, Sensei Biotherapeutics has reported progress in its cancer treatment trial. The company's drug, SNS-101, has shown preliminary signs of clinical activity in several tumor types, with more data expected to be published in the fourth quarter of 2024. Notably, Stephens initiated coverage on shares of Sensei Biotherapeutics with an Overweight rating and a price target of $5.00, expressing optimism about the company's innovative approach to cancer treatment.
Furthermore, Sensei Biotherapeutics announced the development of a novel antibody, SNS-101, which targets a protein known to suppress immune response in cancer patients. This development represents a significant step in cancer immunotherapy.
On a different note, the company announced the upcoming resignation of its Chief Financial Officer, Erin Colgan, effective April 10, 2024. The company is currently in the process of searching for a new CFO. These are the recent developments for Sensei Biotherapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.